Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: is there a standard of care?

Head and neck cancer, comprising cancers of the oral cavity, larynx, nasopharynx, salivary gland, sinonasal cavity, oropharynx, and hypopharynx, is the 7th most common cancer worldwide [1]. Each year,>930,000 new cases of head and neck cancer are diagnosed, and nearly 470,000 people die from this disease [1]. This includes approximately 66,000 cases and 15,000 deaths in the United States, 153,000 cases and 69,000 deaths in Europe, and 24,000 cases and 8,000 deaths in Japan [2,3]. The majority of head and neck cancers ( ∼90%) are squamous cell carcinomas [4], and most patients (∼60%) are diagnosed with LA SCCHN [5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research